Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Diabetes Mellitus

Background:

• Obesity and type 2 diabetes mellitus (T2DM) present significant clinical challenges, often with treatment plans failing to achieve adequate glycemic control or sustainable weight loss.
• Untreated hypogonadism is increasingly recognized as a contributing factor to treatment resistance in male patients with T2DM and metabolic syndrome.
• The interplay between hypogonadism, metabolic syndrome, and T2DM requires further investigation to optimize patient management.

Purpose of the Study:

• To describe the impact of testosterone therapy on a male patient with hypogonadism, metabolic syndrome, and T2DM.
• To highlight the potential of testosterone replacement in improving glycemic control and facilitating weight loss in this patient population.
• To underscore the importance of evaluating for testosterone deficiency in T2DM patients with abdominal obesity and treatment resistance.

Main Methods:

• A case study approach was employed to detail the clinical presentation and treatment course.
• The patient presented with obesity, T2DM, metabolic syndrome, and diagnosed hypogonadism.
• Testosterone therapy was initiated, and outcomes were monitored over time.

Main Results:

• Testosterone therapy resulted in substantial and sustained body weight loss.
• Significant improvements were observed in critical laboratory values.
• The patient achieved complete remission of diabetes.

Conclusions:

• Hypogonadism is prevalent in men with T2DM and can impede effective treatment.
• Evaluation for testosterone deficiency is crucial in male T2DM patients with significant abdominal fat and inadequate treatment response.
• Testosterone therapy can normalize laboratory values and potentially lead to diabetes remission.